Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 20/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29038922 | 0.88 | EGFR (0.35) | LRRK2 | |
| SCHEMBL17670298 | 0.87 | EGFR (0.51) | — | |
| SCHEMBL17670453 | 0.84 | EGFR (0.37) | LRRK2 | |
| SCHEMBL17670459 | 0.81 | EGFR (0.42) | LRRK2 | |
| SCHEMBL17670158 | 0.79 | PTK2 (0.39) | LRRK2 | |
| SCHEMBL17670333 | 0.79 | SMN1; SMN2 (0.41) | LRRK2 | |
| SCHEMBL30385115 | 0.79 | SMN1; SMN2 (0.41) | LRRK2 | |
| SCHEMBL20987207 | 0.78 | LRRK2 (0.48) | LRRK2 | |
| SCHEMBL30040344 | 0.78 | LRRK2 (0.48) | LRRK2 | |
| SCHEMBL17670139 | 0.78 | EGFR (0.39) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725554-A2 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2026-04-15 | — | — | EP | disclosed |
| US-RE50528-E1 | Compounds and compositions for modulating EGFR mutant kinase activities | YUHAN CORPORATION (KR) | 2025-08-12 | — | — | US | disclosed |
| EP-3929190-B1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORP (KR) | 2024-12-25 | — | — | EP | disclosed |
| EP-4421069-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2024-08-28 | — | — | EP | disclosed |
| EP-3929190-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2021-12-29 | — | — | EP | disclosed |
| EP-3604294-B1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORP (KR) | 2021-05-05 | — | — | EP | disclosed |
| EP-3604294-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2020-02-05 | — | — | EP | disclosed |
| EP-3207035-B1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORP (KR) | 2019-11-20 | — | — | EP | disclosed |
| EP-3207035-A2 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2017-08-23 | — | — | EP | disclosed |
| US-9593098-B2 | Compounds and compositions for modulating EGFR mutant kinase activities | YUHAN CORPORATION (KR) | 2017-03-14 | — | — | US | disclosed |
| WO-2016060443-A2 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORPORATION (KR) | 2016-04-21 | — | — | WO | disclosed |
| US-20160102076-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORPORATION | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102076-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | EGFR, ERBB2, ERBB3 | LRRK2 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.